PPARγ was first demonstrated as having the function of regulating adipocyte differentiation, metabolism, and glucose homeostasis [9]; for this reason, PPARγ agonist is identified as a candidate in diabetes mellitus treatment, such as troglitazone, rosiglitazone, and pioglitazone. Here, PPARG is linked to diabetes mellitus.